Home โบ Liposarcoma
Liposarcoma clinical trials recruiting in the U.S.
19 studies for Liposarcoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX11 studies
- New York City, NY7 studies
- Boston, MA7 studies
- St. Louis, MO5 studies
- Queens, NY5 studies
- Chicago, IL5 studies
- Nashville, TN4 studies
- Miami, FL4 studies
- Tampa, FL4 studies
- Atlanta, GA4 studies
- Edison, NJ4 studies
- Seattle, WA4 studies
- Gainesville, FL3 studies
- Richmond, VA3 studies
- San Diego, CA3 studies
- Louisville, KY3 studies
- Phoenix, AZ3 studies
- Milwaukee, WI3 studies
- Columbus, OH3 studies
- New Rochelle, NY3 studies
- Greenburgh, NY3 studies
- Cleveland, OH3 studies
- Los Angeles, CA3 studies
- Bridgeport, CT3 studies
- New Haven, CT3 studies
- Pittsburgh, PA3 studies
- Aurora, CO3 studies
- Rochester, MN3 studies
- Portland, OR3 studies
By state
- Arizona3 studies
- California7 studies
- Colorado3 studies
- Connecticut4 studies
- Florida6 studies
- Georgia4 studies
- Illinois5 studies
- Kentucky3 studies
- Massachusetts7 studies
- Michigan5 studies
- Minnesota3 studies
- Missouri5 studies
- New Jersey5 studies
- New York7 studies
- Ohio7 studies
- Oregon3 studies
- Pennsylvania4 studies
- Tennessee5 studies
- Texas12 studies
- Virginia5 studies
- Washington4 studies
- Wisconsin3 studies
Recently updated studies
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
Up to age 30 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06541262Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06422806Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT04557449Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Nov 9, 2026 ยท NCT06578624Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Nov 4, 2026 ยท NCT05711615STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 22, 2026 ยท NCT06975293Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 21, 2026 ยท NCT06498648A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
RecruitingPhase 2
Ages 16 to 70 ยท All sexes ยท Updated Oct 9, 2026 ยท NCT07741877Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Oct 7, 2026 ยท NCT04031677A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT06881992A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 17, 2026 ยท NCT06025747A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 16, 2026 ยท NCT06843967Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RecruitingPhase 1
Ages 1 to 21 ยท All sexes ยท Updated Aug 6, 2026 ยท NCT04715191NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RecruitingPhase 1/2
Up to age 30 ยท All sexes ยท Updated Aug 3, 2026 ยท NCT06239272A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Jul 28, 2026 ยท NCT07089992Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Jul 15, 2026 ยท NCT07377747A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Jun 11, 2026 ยท NCT06789172Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RecruitingPhase 1
Ages 1 to 26 ยท All sexes ยท Updated Feb 17, 2026 ยท NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RecruitingPhase 1
Up to age 21 ยท All sexes ยท Updated Nov 3, 2025 ยท NCT06198296From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.